LAG3 and melanoma: As presented at the ASCO 2025 Annual Meeting and the ESMO Congress 2025: In RELATIVITY-098, treatment of patients with stage III/IV resected melanoma with nivolumab and relatlimab compared to nivolumab alone did not significantly change recurrence-free survival, with correlative data pointing to the absence of tumor-infiltrating LAG3+ T cells as a potential reason.